People's Clinical Medical College affiliated to Nanchang University, Nanchang, Jiangxi, China.
Department of Orthopedics, Jiangxi Provincial People's Hospital, Nanchang, Jiangxi, China.
PLoS One. 2022 Mar 14;17(3):e0265264. doi: 10.1371/journal.pone.0265264. eCollection 2022.
Ewing sarcoma-associated transcript 1 (lncRNA EWSAT1) is reported to have a close relationship with the overall survival in many cancers. However, the role of its prognosis and correlations with the clinicopathological features in different cancers haven't been explored yet. Herein, we intend to assess the prognostic value and correlations with the clinicopathological features in several cancers.
PubMed, Embase, Web of Science, and The Cochrane Library were searched for literature review from inception to October 25, 2021. Valid data was extracted to make forest and sensitivity analysis plots using Review Manager 5.4 and Stata software. Hazard ratio (HR) or odds ratio (OR) with 95% confidence interval (CI) was used to evaluate the relationship between different expression of EWSAT1 and patients' prognosis and clinicopathological features.
7 studies were screened for this review, including 550 samples. Meta-analysis showed that high expression of lncRNA EWSAT1 was associated with poor overall survival (OS) (HR = 2.10, 95% CI, 1.60-2.75, p < 0.0001) in cancers reported. In addition, patients in high expression group of EWAST1 tended to have more metastasis (OR = 2.20, 95% CI 1.47-3.31, p = 0.0001), and higher TNM stage (I+II vs. III: OR = 0.34, 95% CI 0.21-0.56, p < 0.0001), but in the same time with higher differentiation (well + moderate vs. Poor: OR = 2.21, 95% CI 1.02-4.76, p = 0.04). Age (OR = 1.47, 95% CI 0.94-2.30, p = 0.09) was not significantly different in patients with aberrant expression of EWSAT1.
Our study shows that high expression of EWSAT1 may indicate poor overall survival and associated with several clinicopathological features, which can be used as a potential prognosis biomarker for multiple cancers.
Ewing 肉瘤相关转录物 1（lncRNA EWSAT1）据报道与许多癌症的总生存率密切相关。然而，其预后价值及其与不同癌症的临床病理特征的相关性尚未得到探索。在此，我们旨在评估其在几种癌症中的预后价值及其与临床病理特征的相关性。
从建库至 2021 年 10 月 25 日，我们在 PubMed、Embase、Web of Science 和 The Cochrane Library 中检索了文献综述。使用 Review Manager 5.4 和 Stata 软件提取有效数据以制作森林图和敏感性分析图。使用风险比（HR）或比值比（OR）及其 95%置信区间（CI）来评估不同 EWSAT1 表达与患者预后和临床病理特征之间的关系。
本综述共筛选出 7 项研究，共纳入 550 例样本。荟萃分析表明，lncRNA EWSAT1 高表达与癌症报告的总体生存（OS）不良相关（HR = 2.10，95%CI，1.60-2.75，p < 0.0001）。此外，在 EWAST1 高表达组的患者中，转移倾向更高（OR = 2.20，95%CI 1.47-3.31，p = 0.0001），且 TNM 分期更高（I+II 期与 III 期：OR = 0.34，95%CI 0.21-0.56，p < 0.0001），但分化程度更高（良好+中等与差：OR = 2.21，95%CI 1.02-4.76，p = 0.04）。在 EWSAT1 异常表达的患者中，年龄（OR = 1.47，95%CI 0.94-2.30，p = 0.09）无显著差异。
我们的研究表明，EWSAT1 的高表达可能预示着整体生存率较差，并与几种临床病理特征相关，可作为多种癌症潜在的预后生物标志物。
